Primecap Management Co. CA Has $46,000 Stock Holdings in Accuray Incorporated $ARAY

Primecap Management Co. CA decreased its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 79.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,700 shares of the medical equipment provider’s stock after selling 127,500 shares during the period. Primecap Management Co. CA’s holdings in Accuray were worth $46,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of ARAY. Williams & Novak LLC raised its holdings in shares of Accuray by 25.5% in the 2nd quarter. Williams & Novak LLC now owns 68,970 shares of the medical equipment provider’s stock worth $94,000 after buying an additional 14,000 shares in the last quarter. Deutsche Bank AG grew its position in Accuray by 44.0% in the first quarter. Deutsche Bank AG now owns 60,606 shares of the medical equipment provider’s stock valued at $108,000 after acquiring an additional 18,526 shares during the period. Algert Global LLC raised its stake in Accuray by 104.7% during the first quarter. Algert Global LLC now owns 60,930 shares of the medical equipment provider’s stock worth $109,000 after acquiring an additional 31,170 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Accuray by 429.3% during the first quarter. Jane Street Group LLC now owns 91,944 shares of the medical equipment provider’s stock valued at $165,000 after acquiring an additional 74,574 shares during the period. Finally, Hsbc Holdings PLC lifted its holdings in shares of Accuray by 15.4% during the first quarter. Hsbc Holdings PLC now owns 122,654 shares of the medical equipment provider’s stock valued at $221,000 after acquiring an additional 16,389 shares during the period. 64.08% of the stock is currently owned by institutional investors.

Accuray Stock Up 2.6%

Shares of NASDAQ ARAY opened at $0.95 on Friday. Accuray Incorporated has a 12-month low of $0.91 and a 12-month high of $2.95. The firm’s 50-day simple moving average is $1.51 and its 200 day simple moving average is $1.46. The company has a quick ratio of 0.92, a current ratio of 1.65 and a debt-to-equity ratio of 1.53. The company has a market cap of $107.55 million, a price-to-earnings ratio of -47.45 and a beta of 1.39.

Accuray (NASDAQ:ARAY) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.13). Accuray had a negative return on equity of 4.92% and a negative net margin of 0.35%.The company had revenue of $93.94 million during the quarter, compared to the consensus estimate of $91.34 million. Accuray has set its FY 2026 guidance at EPS. On average, research analysts expect that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ARAY has been the topic of several analyst reports. BTIG Research lowered their target price on shares of Accuray from $5.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, November 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Accuray in a research note on Wednesday. Finally, Wall Street Zen lowered shares of Accuray from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $4.00.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.